Storgate LLC Makes New $643,000 Investment in Icon Plc $ICLR

Storgate LLC purchased a new position in shares of Icon Plc (NASDAQ:ICLR) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 3,527 shares of the medical research company’s stock, valued at approximately $643,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ICLR. Toth Financial Advisory Corp acquired a new position in Icon during the 4th quarter worth approximately $27,000. Ameriflex Group Inc. acquired a new position in Icon during the 3rd quarter worth approximately $33,000. Johnson Financial Group Inc. acquired a new position in Icon during the 3rd quarter worth approximately $71,000. Quadrant Capital Group LLC acquired a new position in Icon during the 3rd quarter worth approximately $78,000. Finally, Geneos Wealth Management Inc. grew its holdings in Icon by 11.5% during the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after acquiring an additional 56 shares in the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on ICLR shares. JPMorgan Chase & Co. boosted their price target on shares of Icon from $120.00 to $130.00 and gave the stock a “neutral” rating in a report on Friday, May 29th. Leerink Partners set a $145.00 price target on shares of Icon in a report on Thursday, May 28th. Citigroup boosted their price objective on shares of Icon from $120.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, May 29th. Robert W. Baird set a $119.00 price objective on shares of Icon in a research report on Friday, February 13th. Finally, BMO Capital Markets boosted their price objective on shares of Icon from $130.00 to $160.00 and gave the stock an “outperform” rating in a research report on Friday, May 29th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $156.44.

Icon Stock Down 2.5%

Shares of NASDAQ:ICLR opened at $146.18 on Friday. The company has a market capitalization of $11.19 billion, a PE ratio of 23.73, a P/E/G ratio of 11.84 and a beta of 1.26. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.31. Icon Plc has a twelve month low of $66.57 and a twelve month high of $211.00. The firm has a 50 day simple moving average of $121.76 and a 200-day simple moving average of $140.47.

Icon (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, June 17th. The medical research company reported $2.52 earnings per share for the quarter, topping the consensus estimate of $2.47 by $0.05. Icon had a net margin of 5.98% and a return on equity of 9.50%. The business had revenue of $2.11 billion during the quarter, compared to the consensus estimate of $1.99 billion. During the same quarter in the previous year, the firm earned $3.43 EPS. The company’s revenue was up 2.5% compared to the same quarter last year. On average, equities analysts predict that Icon Plc will post 9.74 EPS for the current fiscal year.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.